# **Application for Quotation of Additional Securities**

File Reference:

I:\Publications\Operating Rules\Listing Rules\Forms\NSX Quotation of Additional Securities.doc



# **Table of Contents**

INTRODUCTION	3
MORE INFORMATION AND SUBMISSION OF FORM:	3
NEW ISSUE ANNOUNCEMENT, APPLICATION FOR QUOTATION OF ADDITIONAL SECURITIES AND AGREEMENT	4
PART 1 - ALL ISSUES	4
PART 2 - BONUS ISSUE OR PRO RATA ISSUE	6
PART 3 - QUOTATION OF SECURITIES	8
ADDITIONAL SECURITIES FORMING A NEW CLASS OF SECURITIES	8
QUOTATION AGREEMENT	. 10

#### **Introduction**

...........

To ensure the efficient processing of this form by NSX, please:

- 1. Adhere to the suggested number of the annexures required by this form.
- 2. Complete **all** statements and questions in this form. (NSX can provide an electronic version of this form on request).

#### More Information and Submission of Form:

Further information can be obtained from and all applications should be sent to:

Manager, Admissions Stock Exchange of Newcastle Limited PO BOX 283 Newcastle NSW 2300

Phone: 61 2 4929 6377 Fax: 61 2 4929 1556 http://www.newsx.com.au

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to NSX as soon as available. Information and documents given to NSX become NSX's property and may be made public.

Introd	duced 11 March 2004.	, , , , , ,
	ne of entity SMEDICS AUSTRALIA LIMITED	
CO	SWIEDIOS AOSTRALIA LIIVITED	
ABN	I/ACN	
380	02862017	
We	(the entity) give NSX the following inf	ormation.
	art 1 - All issues must complete the relevant sections (atta	ach sheets if there is not enough space)
1	Class of securities issued or to be issued	ORDINARY SHARES
•	No alternative of the control of the	10.055.500
2	Number of securities issued or to be issued (if known) or maximum number which may be issued	13,255,502
3	Principal terms of the securities	
3	(eg, if options, exercise price and expiry date; if partly paid securities, the amount outstanding and due dates for payment; if convertible securities, the conversion price and dates for conversion)	N/A
4	Do the securities rank equally in	ORDINARY SHARES ISSUED RANK EQUALLY
	all respects from the date of allotment with an existing class of quoted securities?	
	If the additional securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	

5 12,500,000 ISSUED AT 20c EACH PURSUANT Issue price or consideration TO SHAREHOLDER APPROVAL FOR THE ACQUISITION OF SSH MEDICAL WORKSTATION PYT LTD AND 755,502 SHARES ISSUED PURSUANT TO EXERCISE OF OPTIONS EXPIRING DECEMBER 31 2005. Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets) 20<sup>1H</sup> JAN 2006 7 Dates of entering securities into uncertificated holdings despatch of certificates Number 8 Number and class of all 66,070,518 ORDINARY SHARES securities quoted on NSX (including the securities in clause SHARE OPTIONS 17,175,000 2 if applicable) DECEMBER '07 @ 13.33c Number Class 9 Number and class of all Nil. securities not quoted on NSX (including the securities in clause 2 if applicable)

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

ALL SHARES RANK EQUALLY FOR ANY FUTURE DIVIDENDS

## Part 2 - Bonus issue or pro rata issue

11	Is security holder approval required?	
12	Is the issue renounceable or non-renounceable?	
13	Ratio in which the securities will be offered	
14	Class of securities to which the offer relates	
15	Record date to determine entitlements	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	
	3 · · · · · · · · · · · · · · · · · · ·	
17	Policy for deciding entitlements in relation to fractions	
18	Names of countries in which the entity has security holders who will not be sent new issue documents	
	Note: Security holders must be told how their	
	entitlements are to be dealt with.	
19	Closing date for receipt of	
. •	acceptances or renunciations	
20	Names of any underwriters	
	rames of any anderwhers	
21	Amount of any underwriting fee or	
<b>4</b> 1	commission	
	COMMISSION	
22	Names of any brokers to the	
22	issue	
	15500	
22	Foo or commission nevertle to the	
23	Fee or commission payable to the	
	broker to the issue	
0.6		
24	Amount of any handling fee	
	payable to brokers who lodge	
	acceptances or renunciations on	
	behalf of security holders	

25	If the issue is contingent on security holders' approval, the date of the meeting	
26	Data antitlement and accentance	
20	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	
28	Date rights trading will begin (if	
20	applicable)	
	,	
29	Date rights trading will end (if applicable)	
30	How do security holders sell their entitlements <i>in full</i> through a broker?	
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	
32	How do security holders dispose of their entitlements (except by sale through a broker)?	
33	Despatch date	

# Part 3 - Quotation of securities

You n	eea on	ly complete this section if you are applying for quotation of securities		
34	Type of securities (tick one)			
(a)	X	Securities described in Part 1		
(b)		All other securities  Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities		
Entitie	es that	have ticked box 34(a)		
Addit	tional	securities forming a new class of securities		
	o indica cument	ate you are providing the information s		
35	X	If the securities are equity securities, the names of the 20 largest holders of the additional securities, and the number and percentage of additional securities held by those holders (Appendix 1)		
36	X	If the securities are equity securities, a distribution schedule of the additional securities setting out the number of holders in the categories 1 - 1,000		
37		A copy of any trust deed for the additional securities		
Entitie	es that	have ticked box 34(b)		
38		per of securities for which ation is sought		
39	Class of securities for which			
	quota	ation is sought		

A	1		-1		
Application	m	anoration	OI	addillonal	securines

40	Do the securities rank equally in all respects from the date of allotment with an existing class of quoted securities?		
	If the additional securities do not rank equally, please state:  the date from which they do  the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now		
	Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another security, clearly identify that other security)		
		Number	Class
42	Number and class of all securities quoted on NSX ( <i>including</i> the securities in clause 38)		

#### Quotation agreement

- 1 Quotation of our additional securities is in NSX's absolute discretion. NSX may quote the securities on any conditions it decides.
- 2 We warrant the following to NSX.
  - The issue of the securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those securities should not be granted quotation.
  - An offer of the securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any securities to be quoted and that no-one has any right to return any securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the securities be quoted.
- We warrant that if confirmation is required under section 1017F of the Corporations Act in relation to the securities to be guoted, it has been provided at the time that we request that the securities be quoted.
- If we are a trust, we warrant that no person has the right to return the securities to be quoted under section 1019B of the Corporations Act at the time that we request that the securities be quoted.
- 3 We will indemnify NSX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- 4 We give NSX the information and documents required by this form. If any information or document not available now, will give it to NSX before quotation of the securities begins. We acknowledge that NSX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:

(Director/Company secretary)

Print name: **Bronte Douglass**  Date: 20.1.06

## Appendix 1

#### 35. **20 LARGEST HOLDERS OF ADDITIONAL SECURITIES**

SHAREHOLDER	SHARES ACQUIRED	% OF ISSUED CAPITAL
SSH Medical Limited	12,500,000	94.3
J. Lee	110,000	0.82
D. Lee	100,000	0.75
S. Cates	34,752	0.26
Wallace A. Booth	15,000	0.11
Lowtal Pty Ltd	12,000	0.09
Neil & Jill Bannerman	9000	0.067
Patricia Mary Burke	9000	0.067
12 Unrelated Holders at	6500 each	0.049 each